First Oral Option for Dermatomyositis Gets FDA Green Light

The FDA has approved the first oral medication specifically designed for dermatomyositis, an autoimmune disorder characterized by chronic inflammation, muscle weakness, and skin rashes. Brepocitinib (Lisraya) is a TYK2/JAK1 inhibitor that targets the root cause of the disease, offering a promising treatment option for patients who have struggled with few effective therapies.

The approval comes after a phase III, placebo-controlled trial called VALOR, which involved 241 adults with treatment-resistant dermatomyositis. The study demonstrated that brepocitinib significantly improved patient outcomes, with higher doses yielding greater improvements in mobility and function compared to placebo. Notably, 45% of patients on brepocitinib discontinued corticosteroids, and 62% reduced their steroid use, indicating a positive change in the patients' overall health.

While the safety profile of brepocitinib is similar to other treatments for dermatomyositis, with rates of adverse events (AEs) around 86-91%, the most common adverse events included upper respiratory tract infection, COVID, urinary tract infections, nausea, diarrhea, and headaches. Despite these minor side effects, the FDA's approval of Lisraya represents a significant advancement in dermatomyositis treatment, providing patients with a targeted, effective, and oral therapy to manage their condition and improve their quality of life.